Obesity Increases Risk-Adjusted Morbidity, Mortality, and Cost Following Cardiac Surgery

Ravi K Ghanta1, Damien J LaPar2, Qianzi Zhang3

  • 1Baylor College of Medicine, Houston, TX ghanta@bcm.edu.

Insights

Obesity significantly increases cardiac surgery costs and risks. Higher body mass index (BMI) is linked to greater mortality, complications like renal failure and infections, and increased hospital expenses.

Area of Science:

  • Cardiovascular Surgery
  • Obesity Medicine
  • Health Economics

Background:

  • Rising obesity rates present challenges in healthcare.
  • Limited data exists on obesity's impact on cardiac surgery costs.
  • This study investigates the relationship between body mass index (BMI) and outcomes/costs in cardiac surgery patients.

Purpose of the Study:

  • To determine if increasing BMI correlates with adverse risk-adjusted outcomes after cardiac surgery.
  • To assess the association between BMI and hospital costs for patients undergoing cardiac procedures.

Main Methods:

  • Analysis of 13,637 cardiac surgery patients from a Society of Thoracic Surgeons database.
  • Patients categorized by BMI: normal/overweight (18.5-30), obese (30-40), and morbidly obese (>40).
  • Outcomes and costs compared across BMI groups and modeled continuously, adjusting for preoperative risk scores.

Main Results:

  • Morbidly obese patients had ~60% higher mortality, >2x renal failure, and 6.5x deep sternal wound infections compared to normal weight patients.
  • Risk-adjusted analysis confirmed BMI's significant association with mortality (P<0.001) and major morbidity (P<0.001).
  • Risk-adjusted hospital costs increased with BMI, with morbidly obese patients incurring 17.2% higher costs.

Conclusions:

  • Elevated BMI is independently associated with increased mortality, major morbidity, and healthcare costs following cardiac surgery.
  • BMI should be a more significant factor in risk stratification and resource allocation for these patients.
Abstract

Related Concept Videos

Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
405
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.4K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
588
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
331
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
558